Akeso Secures NMPA Nod for Gumokimab in Psoriasis, Expanding Autoimmune Portfolio
Event summary
- Akeso's gumokimab (AK111) approved by NMPA for moderate-to-severe plaque psoriasis on June 11, 2026.
- Phase III trial showed 94.6% PASI 75 response rate and 47.7% PASI 100 clearance at Week 12.
- Drug requires only 17 injections annually, half the burden of competitors.
- Supplemental NDA for active ankylosing spondylitis accepted for review by CDE.
The big picture
Akeso's approval strengthens its position in China's growing autoimmune disease market, where it now offers two distinct therapeutic pathways for psoriasis. The company is positioning itself as a major player in immunology, with a pipeline that includes multiple first-in-class candidates. This approval comes as global demand for targeted biologics in dermatology continues to rise, particularly in emerging markets.
What we're watching
- Pipeline Expansion
- Whether Akeso can sustain its rapid development of autoimmune therapies across multiple indications.
- Market Penetration
- The pace at which gumokimab gains market share against established IL-17 inhibitors in China.
- Regulatory Momentum
- How quickly the sNDA for ankylosing spondylitis progresses through NMPA review.